MSC-AAT

MSC-AAT



MSC-AAT


MSC-AAT is a genetically modified mesenchymal stem cell engineered to constitutively overexpress and secrete alpha-1 antitrypsin (AAT), a serine protease inhibitor with potent anti-inflammatory and immunomodulatory properties. By combining the paracrine immunomodulatory activity of MSCs with local delivery of AAT, MSC-AAT suppresses T-cell proliferation, inhibits neutrophil elastase and proteinase-3, and polarises macrophages toward an anti-inflammatory phenotype — more effectively than either unmodified MSC or systemic AAT therapy alone.

The primary indication is steroid-refractory acute graft-versus-host disease (SR-aGvHD) in adult patients. In a Phase I/II clinical study, AAT improved clinical outcomes in 8 of 12 patients with SR-aGvHD. In a preclinical haploidentical stem cell transplantation model, MSC-AAT extended median survival from 22 to 38 days compared to naïve MSC. MSC-AAT has received regulatory approval for Phase I/II clinical trials in Germany and is prepared for IND-enabling studies in the United States. In December 2024, the FDA approved RYONCIL® (remestemcel-L) as the first MSC therapy for paediatric SR-aGvHD, validating the MSC approach for this indication and creating immediate market opportunity for MSC-AAT in the adult population.

In rheumatoid arthritis (RA), MSC-AAT targets the dysregulated synovial inflammation driving joint destruction. AAT inhibits the pro-inflammatory proteases and NF-κB signalling central to RA pathophysiology, and in preclinical collagen-induced arthritis models has demonstrated reductions in joint inflammation and cartilage erosion.

Additional indications include type 1 diabetes (T1D) — where a Phase II randomised controlled trial demonstrated significant improvement in C-peptide production and HbA1c following AAT therapy — and chronic obstructive pulmonary disease (COPD), where MSC-AAT overcomes the critical limitation that only approximately 4% of intravenously administered AAT reaches the lungs by homing directly to pulmonary tissue.



Next steps

Next steps




Kyttaro is poised to conclude preclinical partnerships for MSC-Klotho and commence discussions with the FDA to initiate a Phase I/ II clinical study in GvHD in the US. We invite interested partners to contact us for more details.
Kyttaro is poised to conclude preclinical partnerships for MSC-Klotho and commence discussions with the FDA to initiate a Phase I/ II clinical study in GvHD in the US. We invite interested partners to contact us for more details.